South San Francisco, Calif. --- April 17, 2013 --- A new study shows that the number of patients with thyroid nodules who undergo surgery – increasingly to remove all, rather than part, of their thyroid – has risen by 31% over five years, Veracyte announced today.
South San Francisco, Calif. --- April 12, 2013 --- Veracyte, Inc. , a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Shelly D. Guyer as chief financial officer. “We are delighted to welcome Shelly Guyer to the Veracyte team,”
South San Francisco, Calif. --- March 12, 2013 --- Veracyte, Inc ., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced new study findings showing that when BRAF V600E mutation testing was conducted on ambiguous thyroid nodule samples that were
South San Francisco, Calif. --- March 8, 2013 --- Veracyte, Inc. , a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that UnitedHealthcare, one of the nation’s largest private health insurers, has issued a positive medical coverage policy for the
South San Francisco, Calif. --- February 15, 2013 --- Veracyte, Inc. today announced that a new review article published in PLOS Currents: Evidence on Genomic Tests concludes that published studies and independent assessments and reviews of the Afirma Gene Expression Classifier support the test’s
South San Francisco, Calif. --- January 7, 2013 --- Veracyte, Inc. , a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that, for the first time, molecular testing is now included in the National Comprehensive Cancer Network Clinical Practice
The study adds to the growing body of published data supporting the company's genomic test and underscores the rigorous standards we set for our test's performance
Veracyte and Genzyme Also Announce that Memorial Sloan-Kettering Cancer Center is Among the State’s First Institutions to Offer Genomic Test to Patients with Inconclusive Thyroid Nodule Results
New Study Suggests That Use of Veracyte’s Afirma® Gene Expression Classifier Helps to Significantly Reduce Surgeries in Patients with Ambiguous Thyroid Nodule Cytology Results South San Francisco, Calif. and Cambridge, Mass. — July 17, 2012 — Veracyte, Inc.
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
